Scegliere farmaci personalizzati e valutare il rischio nei neoplasmi gastroenteropancreatici neuroendocrini derivati dai pazienti.

CONTEXT: Precision medicine has transformed many areas in oncology. However, it remains largely unexplored in metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), where there is a need for further innovative therapies. OBJECTIVE: To evaluate individual tumor responses to different agents, we have established a standardized personalized drug screening and risk assessment platform using patient-derived GEP-NEN primary cultures (n = 23, 16/23 from metastatic tumors, n = 12 small intestinal neuroendocrine tumors [siNETs], n = 10 pancreatic NETs [pNETs], n = 1 neuroendocrine carcinoma [NEC]). METHODS: We assessed GEP-NEN primary culture cell viability, performed signaling path